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Objective: Soluble complement receptor type 1 inhibits complement activa-
tion by blocking C3 and C5 convertases of the classical and alternative
pathways. We evaluated the effect of soluble complement receptor type 1 on
lung allograft reperfusion injury. Methods: Left lung transplantation was
performed in 13 weight-matched pigs (25 to 31 kg) after prolonged
preservation (20 hours at 1° C). One hour after reperfusion the recipient
contralateral right lung was excluded to assess graft function only. Com-
plement activity and C3a levels were measured after reperfusion and at the
end of the assessment. Extravascular lung water index, intrathoracic blood
volume, and cardiac output were assessed during a 5-hour observation
period. Gas exchange and hemodynamics were monitored. At the end of the
5-hour assessment period, myeloperoxidase assay and bronchoalveolar
lavage were performed to assess neutrophil migration, and C5b-9 (mem-
brane attack complex) deposits in the allograft were detected by immuno-
histochemistry. Two groups were studied. In group II (n 5 6) recipient
animals were treated with soluble complement receptor type 1 (15 mg/kg)
15 minutes before reperfusion. Group I (n 5 7) served as the control group.
Results: Serum complement activity was completely inhibited in group II. In
contrast to group I, C5b-9 complexes were not detected in group II allograft
tissue samples. C3a was reduced to normal levels in group II (p 5 0.00005).
Extravascular lung water index was higher in group I animals throughout
the assessment period (p 5 0.035). No significant difference in allograft
myeloperoxidase activity (p 5 0.10) and polymorphonuclear leukocyte
count of the bronchoalveolar lavage fluid (p 5 0.057) was detected.
Conclusion: Inhibition of the complement system by soluble complement
receptor type 1 blocks local complement activation in the allograft and
reduces posttransplantation reperfusion edema but does not improve
hemodynamic parameters. (J Thorac Cardiovasc Surg 1998;116:90-7)
The pathophysiology of posttransplantation reper-fusion injury is not completely understood, but
there is much evidence that activation of the non-
specific immune system contributes substantially to
postischemic tissue injury. Mediators of reperfusion
injury include neutrophil granulocytes, oxygen-de-
rived free radical species, and the complement
system.1
Postischemic injury in lung allografts can be re-
duced by leukocyte depletion, inhibition of neutro-
phil adhesion molecules, and administration of ox-
ygen-derived free radical scavengers during
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ischemia and reperfusion. The complement system
is thought to be involved directly by activation of
complement cleavage products and indirectly by
complement-mediated neutrophil activation.2
In vivo, five proteins inhibit the C3 and C5
convertases of the complement system that activate
C3 and C5. One of these proteins, the membrane-
bound complement receptor type 1 (CR1), is not
widely distributed among different cell types and is
expressed only on erythrocytes and leukocytes.3
Elimination of the transmembrane and cytoplas-
matic domains results in a soluble form of CR1.4
The remaining extracellular recombinant soluble
domain of the complement receptor type 1 (sCR1)
retains the inhibitory function on complement acti-
vation by inhibiting C3 and C5 convertases of both
the classical and alternative pathways. In vivo stud-
ies demonstrate that sCR1 is a potent inhibitor of
complement-dependent lung and dermal vascular
injury and reduces vascular permeability and neu-
trophil tissue accumulation.5
sCR1 reduces postischemic reperfusion in the
myocardium,4, 6, 7 skeletal muscle,8 and the liver.9 A
phase I/II trial in lung transplant recipients is
planned in the United States to evaluate the effect of
sCR1 on posttransplantation lung graft function
(Una Ryan, T-cell Science Inc., Needham, Mass.).
In the present study we evaluated the effect of
recombinant human sCR1 on reperfusion injury in a
large animal model of unilateral lung allotransplan-
tation. The swine model was chosen because human
recombinant sCR1 is not effective in other large
animals, as for example the dog.
Materials and methods
Thirteen weight-matched pairs of outbred pigs (aged 3
to 4 months) served as donors and recipients. Harvest and
left lung transplantation were performed by a modifica-
tion of the standard technique performed in dogs as
described previously.10
Donor procedure. Lungs were harvested from animals
whose lungs were ventilated with 100% oxygen and 5 cm
H2O of positive end-expiratory pressure. Before adminis-
tration of the flush solution (1.5 L, 4° C, Perfadex, P&U/
Biophausia AB, Uppsala, Sweden), 250 mg alprostadil
(Prostin VR Pediatric; The Upjohn Company, Kalama-
zoo, Mich.) was injected directly into the main pulmonary
artery to achieve maximal vasodilation. The harvested
organs were stored in low-potassium-dextran solution
(1° C) for 20 hours before implantation.
Recipient procedure. Implantation was performed us-
ing standard technique. One hour after reperfusion, the
right main pulmonary artery, the arterial branch to the
upper lobe, and the right intermediate bronchus were
ligated to assess allograft function. The right upper lobe
was excluded from ventilation by advancing the tracheal
tube to the carina.
Study groups. In group II (n 5 6) sCR1 (generously
provided by T-cell Sciences Inc., Needham, Mass.) was
given to the recipient 15 minutes before reperfusion at a
dose of 15 mg/kg. Group I (n 5 7) served as control, and
no sCR1 was administered. sCR1 was stored at –70° C in
aliquots, underwent one thaw-freeze cycle, and was pre-
pared before use.
All animals received humane care in compliance with
the “Principles of Laboratory Animal Care” formulated
by the National Society for Medical Research and the
“Guide for the Care and Use of Laboratory Animals”
prepared by the National Academy of Science and pub-
lished by the National Institutes of Health (NIH publica-
tion No. 85-23, revised 1985). The protocol was approved
by the local animal study committee.
Assessment. During the assessment period anesthesia
was maintained with halothane (Fluothane) 1.0% to 1.5%.
Systemic arterial, pulmonary arterial, central venous, and
left atrial pressures were recorded continuously. Arterial
and mixed venous blood was collected for gas analysis
every 30 minutes. At the end of the assessment period, 5
hours after reperfusion, the animals were killed. Upper
lobe allograft samples were submitted to histologic exam-
ination and tissue myeloperoxidase assay.
Measurement of extravascular lung water. We modi-
fied the previously used large animal model of lung
allograft reperfusion injury by the measurement of ex-
travascular lung water as direct assessment of reperfusion
edema. A fiberoptic catheter (System Cold Z-021, Pul-
sion, Munich, Germany) is advanced via the external
carotid artery into the descending aorta. The indicator
bolus consists of two components. Indocyanine green
serves as intravascular marker and ice cold 5% glucose as
a thermal intravascular and extravascular indicator. The
bolus is injected via the external jugular vein with a
temperature-controlled injector. The dilution curves for
dye and temperature are recorded simultaneously in the
descending aorta with the thermistor-tipped fiberoptic
catheter.
Thoracic intravascular and extravascular fluid volumes
are determined on the basis of the measurement of the
mean transit times for thermal and dye indicators and of
the decay time volumes calculated from the indicator-
dilution curves as described previously.11 The lung water
computer (System Cold Z-021, Pulsion, Munich, Ger-
many) determines the mean transit time for the thermal
indicator and for the dye indicator and calculates total
thermal volume (ITTV), intrathoracic blood volume
(ITBV), and extravascular thermal volume (ETV).12 The
extravascular thermal volume (ETV) is calculated as
follows: ETV 5 ITTV – ITBV. All measurements were
made every 30 minutes for the first 3 hours and hourly
thereafter in triplicate. The mean value was used for
analysis.
Assessment of serum complement activity (CH50). The
inhibitory effect of sCR1 on the swine complement system
was confirmed with Meyer’s hemolysis method to measure
complement activity (CH50) as described previously
13
(courtesy of Dr. P. Spa¨th, Zentral laboratorium SRK,
Berne, Switzerland).
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CH50 in the recipient’s serum was detected by the same
method at the time of reperfusion and at the end of the
assessment period 5 hours after reperfusion.
Membrane attack complex (C5b-9, MAC). Levels of
membrane attack complex (MAC) were determined in the
pulmonary venous blood by enzyme-linked immunosor-
bent assay. Zymosan-activated human serum was used as
standard defining arbitrary units (AU/ml). MAC deposi-
tion in the pulmonary allograft was detected by immuno-
histochemistry with the use of the same mouse anti-
human C9-antibody (C9-neoepitope, clone aE11) that is
cross-reactive in pigs.14 Tissue samples were taken at the
end of the 5-hour assessment period.
Myeloperoxidase assay. Lung samples were frozen im-
mediately and stored at –70° C until assay. Quantitative
myeloperoxidase activity was determined as previously
described.10
Statistical analysis. All values are given as the mean 6
standard error of the mean and, where appropriate, the
95% confidence interval of the mean (95% CI) is added.
Donor weight, recipient weight, preservation time, warm
ischemic time, CH50 activity, C5b-9 activity, C3a levels,
neutrophil count in bronchoalveolar lavage fluid, and
myeloperoxidase assay were checked for normal distribu-
tion within groups and analyzed by the unpaired t test. Gas
exchange, hemodynamic parameters, and extravascular
lung water were assessed by repeated-measures analysis of
variance and planned comparison was applied. For anal-
ysis the Statistica 5.1 Software by StatSoft, Inc., Tulsa,
Oklahoma (1997), was used.
Results
Characteristics of experimental groups. No sta-
tistical differences between groups were noted in
donor weight (25.6 6 1.5 kg in group I vs 26.9 6 1.3
kg in group II, p 5 0.54), recipient weight (25.6 6
2.1 kg in group I vs 26.5 6 1.2 kg in group II, p 5
0.73), preservation time (1209 6 7 minutes in group
I vs 1195 6 4 minutes in group II, p 5 0.13), and
warm ischemic time (81 6 4 minutes in group I vs
89 6 4 minutes in group II, p 5 0.23).
Mortality. Two animals were excluded from anal-
ysis. One animal in group I died of mechanically
induced ventricular fibrillation after occlusion of the
native right pulmonary artery. The second animal
(group II) had fever (temperature . 40° C) and
severe leukocytosis (.45 3 103/ml) during the as-
sessment period. For analysis the control group (n 5
6) was compared with the sCR1-treated group (n 5
5).
Serum complement activity
In vitro. Serum complement activity after addi-
tion of sCR1 in normal swine serum assessed by
CH50 was markedly reduced at a concentration of 15
ng/ml (9 U/ml) and completely inhibited at a con-
centration of 150 ng/ml (Fig. 1).
In vivo. CH50 was assessed in both groups at the
time of reperfusion after administration of sCR1
and at the end of the assessment period 5 hours
after reperfusion. In group II, CH50 was almost
completely blocked at the time of reperfusion
(0.25 6 0.25 U/ml, 95% CI –0.55 to 1.05 U/ml) and
at the end of the assessment (5.25 6 4.27 U/ml, 95%
CI –8.33 to 18.84 U/ml) (p 5 0.000062). In group I,
CH50 was 257.5 6 26.0 U/ml (95% CI 174.7 to 340.3
U/ml) at the time of reperfusion and 247.5 6 21.3
U/ml (95% CI 179.6 to 315.4 U/ml) at the end of the
assessment (p 5 0.000031) (Fig. 2).
C5b-9 and immunohistochemistry. Levels of
C5b-9 (MAC) in the pulmonary venous blood after
the ligation of the contralateral native lung did not
differ between groups (0.47 6 0.14 AU/ml (95% CI
0.096 to 0.856 AU/ml) in group I versus 0.29 6 0.05
AU/ml (95% CI 0.143 to 0.433 AU/ml) in group II
immediately after occlusion (p 5 0.24) and 0.37 6
0.133 AU/ml (95% CI 0.008 to 0.744 AU/ml) in
group I versus 0.19 6 0.03 AU/ml (95% CI 0.133 to
0.275 AU/ml) in group II at the end of the assess-
ment (p 5 0.22).
Immunohistochemistry demonstrated substantial
MAC deposition in group I, whereas in sCR1-
treated animals no MAC deposits were detected
(Fig. 3).
Fig. 1. Representative example of inhibition of the com-
plement system by sCR1 in normal swine serum at differ-
ent concentrations. Complement activity (CH50) was
strongly reduced at a concentration of 15 ng/ml and
completely blocked at concentrations higher than 150
ng/ml.
The Journal of Thoracic and
Cardiovascular Surgery
July 1998
9 2 Schmid et al.
C3a levels. Levels of C3a in the pulmonary ve-
nous blood 1 hour and 4 hours after ligation of the
contralateral native lung were very high in control
animals but remained in the normal range (181 6 50
ng/ml) in sCR1-treated animals (1 hour: 5020 6 617
ng/ml [95% CI 3305 to 6734 ng/ml] vs 164.6 6 19.0
ng/ml [95% CI 111.9 to 217.3 ng/ml], p 5 0.00005; 4
hours: 4053 6 442 ng/ml [95% CI 2824 to 5282
ng/ml] vs 134.5 6 13.8 ng/ml [95% CI 96.2 to 172.7
ng/ml], p 5 0.000021) (Fig. 4).
Gas exchange. No significant difference between
groups was observed in gas exchange over the entire
assessment period (p 5 0.67). Arterial oxygen ten-
sion 1 hour after occlusion in group I was 72.1 6 2.7
kPa versus 64.0 6 4.7 kPa in group II; 4 hours after
reperfusion, arterial oxygen tension in group I was
64.6 6 6.8 kPa versus 67.4 6 5.7 kPa in group II.
Hemodynamics. No significant overall group dif-
ference was noted in cardiac output (p 5 0.28),
intrathoracic blood volume (p 5 0.54), and pulmo-
nary vascular resistance (p 5 0.18) during the 4-hour
assessment period (Figs. 5 and 6).
Extravascular lung water index. Extravascular
lung water index was significantly reduced in group
II in comparison with group I over the entire
assessment period (overall group difference p 5
0.035). The difference between groups was most
pronounced in the first measurement after occlusion
(7.7 6 0.6 ml/kg [95% CI 6.2 to 9.2 ml/kg] vs 5.8 6
0.4 ml/kg [95% CI 4.5 to 7.0 ml/kg], p 5 0.033) and
2 hours after exclusion of the contralateral lung
(10.1 6 0.7 ml/kg [95% CI 8.4 to 11.8 ml/kg] vs 8.3 6
0.5 ml/kg [95%CI 6.9 to 9.7 ml/kg], p 5 0.069). At
the end of the 4-hour assessment period after exclu-
sion of the contralateral lung, extravascular lung
water index decreased to 8.7 6 0.5 ml/kg in group I
versus 7.6 6 0.3 ml/kg in group II (p 5 0.11) (Fig. 7).
Neutrophil count in bronchoalveolar lavage fluid.
Neutrophil count in the bronchoalveolar lavage fluid
of sCR1-treated animals was reduced from 10.5 6
2.6 106 polymorphonuclear leukocytes per milliliter
(PMN/ml) (95% CI 3.2 to 17.8 106 PMN/ml) in
group I to 4.6 6 0.42 106 PMN/ml (95% CI 3.4 to 5.8
106 PMN/ml) in group II (p 5 0.057) (Fig. 8).
Myeloperoxidase assay. Allograft myeloperoxi-
dase activity in group II was lower than that in group
I—0.8 6 0.1 DOD/mg per minute (95% CI 0.5 to 1.1
DOD/mg per minute) versus 1.1 6 0.1 DOD/mg per
minute (95% CI 0.8 to 1.4 DOD/mg per minute)
(p 5 0.10). Myeloperoxidase activity in normal
unflushed lung tissue was 0.7 DOD/mg per minute
(Fig. 8).
Comment
The complement system is part of the humoral
first line of defense and a primary mediator of the
inflammatory process. Activation of the comple-
ment cascade results in interactions between its
various components, leading to the generation of
products that mediate important immunologic pro-
cesses. These include promotion of leukocyte acti-
vation and chemotaxis through receptor-mediated
mechanisms2 and the release of proinflammatory
intermediate products of the complement cascade
(e.g., C3 and C5). The end product of the comple-
ment system is a macromolecular complex, the
membrane attack complex (MAC, C5b-C9), which is
able to form a channel through the plasma mem-
brane and cause target cell lysis.
The complement system is activated by two sep-
arate pathways. The classical pathway is activated by
immune complex formation and therefore inactive
until the body is challenged with antigen to which it
was previously exposed. This condition does not
generally occur in allograft recipients. The alterna-
tive pathway is activated by nucleophilic chemical
structures on the target surface. C3 is cleaved con-
tinuously at a slow rate, forming C3b that binds on
target surfaces. This process is modulated by regu-
lators of complement activation. If the balance is
shifted toward activation by C3b deposition onto a
target surface, an explosive positive feedback loop is
established, thereby overwhelming the endogenous
inhibitors of complement activation.2
The exact mechanism of complement activation
during lung allograft reperfusion remains unknown.
It has been shown that oxygen-derived free radicals
Fig. 2. Complement activity (CH50) in the recipient ani-
mals of the control group and the sCR1-treated group
after reperfusion of the transplanted lung (0 hr) and at the
end of the assessment period (5 hr) (mean 6 standard
error of the mean).
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convert C5 into an active C5b-like form and that
neutrophil-derived hydrogen peroxide activates the
complement system. Metabolically active cells main-
tain defense mechanisms that protect them against
complement attack. Ischemia and reperfusion could
impair their defense by damaging membrane pro-
teins.15
Complement cleavage products have a vast num-
ber of effects that potentially mediate ischemia-
reperfusion injury. C3a and C5a are extremely po-
tent proinflammatory mediators. C5a is 10-fold to
100-fold more active than C3a, but C3 is present in
20-fold greater concentration in the plasma. C3a
and C5a induce vasoconstriction, increase vascular
permeability, and stimulate granulocyte degranula-
tion.16 Furthermore, C5a induces neutrophil adhe-
sion (expression of CD11b/CD18, shedding of L-
selectin),17 activates endothelial cells, and induces
the production of cytokines. C3b and iC3b, its
enzymatically inactivated breakdown product, serve
as accessory adhesion molecules and bind to CD11b/
CD18.
Nonlytic amounts of C5b-C9 (MAC) increase
permeability of the target cell membrane, release
Fig. 3. a and b, Dense deposits of MAC (terminal complement complex, C5b-9) were detected by
immunohistochemistry in allograft tissue samples 5 hours after reperfusion. c and d, In sCR1-treated
animals no deposits of MAC were detected in the allograft tissue (original magnification 3 320).
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calcium from intracellular stores, and initiate
signaling cascades. This results in activation of a
variety of cell functions, including the release of
reactive oxygen-derived radicals, production of
prostaglandins and leukotrienes,18 and secretion
of cytokines. Therefore complement activates a
wide range of cells without requiring specific
receptors.19 In endothelial cells, Ca21-dependent
activation by C5b-9 induces P-selectin release
from Weibel-Palade bodies to the endothelial
membrane.20
In vivo, sCR1 effectively suppresses complement
activation in low doses and reduces inflammatory
tissue damage in models of myocardial infarction
associated with reperfusion injury.4, 21 After lower
torso ischemia-reperfusion, sCR1 reduces lung in-
jury induced by interleukin-2, endotoxin (accelerat-
ed by platelet-activating factor), and pulmonary
albumin leak.22-24
Fig. 4. C3a levels in the pulmonary venous blood in the
recipients were tremendously increased in the control
group 1 hour and 4 hours after reperfusion of the trans-
planted lung. sCR1 treatment completely blocked activa-
tion of the complement system after lung allograft reper-
fusion. Normal range of C3a in swine is 181(50 ng/ml
(mean 6 standard error of the mean).
Fig. 5. Cardiac output in both groups decreased after
occlusion of the right native lung 60 minutes after reper-
fusion. There is no statistical difference between groups
(mean 6 standard error of the mean).
Fig. 6. Pulmonary vascular resistance (PVR) increased at
the time of exclusion of the right native lung. sCR1
treatment did not ameliorate this increase in pulmonary
vascular resistance (mean 6 standard error of the mean).
Fig. 7. Extravascular lung water index (EVLWI) in the
pulmonary allograft increased during the first 150 minutes
after occlusion of the right native lung (60 minutes),
followed by a slight decrease over the next 150 minutes in
both groups. Extravascular lung water index was signifi-
cantly higher in the control group than in the sCR1-
treated group (p 5 0.035) (mean 6 standard error of the
mean).
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In piglets undergoing cardiopulmonary bypass for
2 hours, the increase in pulmonary vascular resis-
tance to 338% of baseline in controls was reduced to
147% of baseline in sCR1-treated animals. Gas
exchange and leukocyte sequestration were not af-
fected in this model.25 However, cardiopulmonary
bypass in complement-deficient dogs resulted in
reduced neutrophil activation, as assessed by CD18
expression.26
For the present study, development of reperfu-
sion edema was assessed by a lung water computer
that determines extravascular thermal volume as a
very reliable measurement of extravascular lung
water. In vivo data confirm that extravascular ther-
mal volume correlates excellently with postmortem
extravascular lung water27 and morphologic classifi-
cation of lung edema.28 However, clinical data re-
vealed only a weak correlation between extravascu-
lar thermal volume and the clinical indices of
pulmonary dysfunction oxygenation and chest radi-
ography.29, 30 It seems therefore that extravascular
thermal volume is more closely related to the sever-
ity of the pathologic status of the lung than is gas
exchange, which is used in most reperfusion studies
as measurement for reperfusion injury.
We demonstrated that the complement system is
activated locally with highly increased deposition of
the terminal complement complex (MAC) in the
allograft tissue. In sCR1-treated animals no MAC
deposits were detected and therefore both the clas-
sical and the alternative pathways of complement
activation were inhibited by sCR1.
The inhibition of the complement system during
reperfusion of lung allografts reduced reperfusion
edema in this system but did not improve hemody-
namic parameters and pulmonary vascular resis-
tance. In sCR1-treated animals a tendency toward a
reduced neutrophil migration into the graft was
detected. This may indicate that inhibition of the
complement system reduces neutrophil activation
during reperfusion. In addition, sCR1-treated recip-
ients demonstrated a tendency toward a better gas
exchange of the lung grafts 5 hours after reperfu-
sion, and no deaths resulting from cardiopulmonary
failure were observed in this group. In contrast, in
the control group, two animals had severe reperfu-
sion edema with rapid deterioration of gas ex-
change.
Even though only a limited effect on graft func-
tion can be expected by an intervention targeted at
a single mechanism of the nonspecific immune
system, we were able to demonstrate that sCR1
reduces lung allograft reperfusion edema and blocks
local complement activation in the allograft. In
combination with inhibition of other arms of the
inflammatory response, the administration of sCR1
before lung allograft reperfusion may be important
to prevent early graft failure.
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